Fatima Jinnah Medical University, Lahore, Pakistan.
Punjab Medical College, Faisalabad, Pakistan.
Medicine (Baltimore). 2023 Jun 9;102(23):e33978. doi: 10.1097/MD.0000000000033978.
Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them.
PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines.
A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women.
While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms.
超过 75%的绝经后妇女会出现血管舒缩症状（VMS），如盗汗和热潮红。尽管这些症状很常见，但对于缓解这些症状的非激素疗法的数据有限。
在 PubMed、Cochrane、Scopus、Ovid、Web of Science 和 ClinicalTrials.gov 上搜索相关研究。搜索使用了以下自定义的关键词，以适应特定的数据库/注册处：更年期、女性、神经激肽 3 和/或 Fezolinetant。搜索截至 2022 年 12 月 20 日进行。本系统评价符合 PRISMA 声明 2020 指南。
共发现 326 条记录，其中有 10 项研究（纳入 1993 名女性）被纳入。这些女性每天接受两次 40 毫克剂量的 NK1/3 受体拮抗剂治疗，随访时间为 1 至 3 周。有中度强证据表明，NK1/3 受体拮抗剂可以帮助限制绝经后妇女热潮红的频率和严重程度。
虽然在进一步的临床试验验证 NK1/3 受体拮抗剂在绝经后妇女中的疗效和安全性之前，这些结果应谨慎解释，但这些发现表明它们是未来针对血管舒缩症状的药理学和临床研究的有前途的靶点。
